ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.

Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The complaint alleges that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price fell from $7.71 to $3.61, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]